Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335179 · ClinicalTrials.gov registry record · Phase 2
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
A Phase 2 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00335179 is a Phase 2 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT00335179, a Phase 2 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should also be visible using a special microscope. This study examines both types of changes.
Interventions
- DRUG Vehicle cream
- DRUG Aldara (imiquimod 5% cream)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335179
The ClinicalTrials.gov registry entry for NCT00335179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT00335179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335179 about?
NCT00335179 is a clinical study titled "Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream". Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should also be visible using a special microscope. This study examines both types of changes.
What is the current status of trial NCT00335179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2003-01. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00335179?
The interventions under investigation include: Vehicle cream (DRUG), Aldara (imiquimod 5% cream) (DRUG).
Who is sponsoring clinical trial NCT00335179?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.